Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rocket Pharmaceuticals (RCKT) and Moderna (MRNA)

Tipranks - Tipranks - Mon Apr 6, 1:22PM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rocket Pharmaceuticals (RCKT) and Moderna (MRNA).

Easter Sale - 70% Off TipRanks

Rocket Pharmaceuticals (RCKT)

In a report issued on April 2, Tessa Romero from J.P. Morgan maintained a Sell rating on Rocket Pharmaceuticals. The company’s shares closed last Thursday at $3.55.

According to TipRanks.com, Romero is a 4-star analyst with an average return of 12.9% and a 46.7% success rate. Romero covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals, ACADIA Pharmaceuticals, and Edgewise Therapeutics. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Rocket Pharmaceuticals with a $9.33 average price target, a 166.6% upside from current levels. In a report issued on March 27, Goldman Sachs also maintained a Sell rating on the stock with a $3.00 price target.

See the top stocks recommended by analysts >>

Moderna (MRNA)

Bernstein analyst Courtney Breen maintained a Hold rating on Moderna on April 3. The company’s shares closed last Thursday at $49.20, close to its 52-week low of $29.25.

According to TipRanks.com, Breen is a 4-star analyst with an average return of 19.4% and a 84.1% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Gilead Sciences, and Merck & Company. ;'>

Currently, the analyst consensus on Moderna is a Hold with an average price target of $37.14, which is a -22.9% downside from current levels. In a report issued on March 31, Goldman Sachs also maintained a Hold rating on the stock with a $41.00 price target.

Read More on RCKT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).